🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

13 results for “MoonLake Immunotherapeutics” Clear

  1. Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration., Skyrizi 150 mg solution for injection in pre-filled syringe, Sonelokimab, Sonelokimab

    MoonLake Immunotherapeutics

    psoriatic arthritis

    phase 3 small molecule active

    1 trial

  2. Sonelokimab

    MoonLake Immunotherapeutics

    Hidradenitis Suppurativa

    phase 3 small molecule active

    4 trials

  3. Sonelokimab

    MoonLake Immunotherapeutics

    psoriatic arthritis (PsA)

    phase 3 small molecule active

    1 trial

  4. Sonelokimab

    MoonLake Immunotherapeutics

    Hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  5. Sonelokimab

    MoonLake Immunotherapeutics

    Arthritis, Psoriatic

    phase 3 small molecule active

    4 trials

  6. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  7. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  8. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (pfs) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  9. 68Ga-FAPI-46, Sonelokimab

    MoonLake Immunotherapeutics

    psoriatic arthritis, axial spondyloarthritis

    phase 2 small molecule active

    1 trial

  10. Sonelokimab

    MoonLake Immunotherapeutics

    axial spondyloarthritis

    phase 2 small molecule active

    1 trial

  11. Sonelokimab

    MoonLake Immunotherapeutics

    Palmoplantar Pustulosis

    phase 2 small molecule active

    1 trial

  12. Sonelokimab (M1095)

    MoonLake Immunotherapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  13. Sonelokimab

    MoonLake Immunotherapeutics

    Relative Bioequivalence

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources